<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>GLENMARK</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">GLENMARK</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="glenmark-pharmaceuticals-limited" class="section level1">
<h1>Glenmark Pharmaceuticals Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLENMARK.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLENMARK.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLENMARK.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLENMARK.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLENMARK.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLENMARK.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLENMARK.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLENMARK.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.GLENMARK.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<p>Based on a comprehensive analysis of the provided financial disclosures, earnings report, auditor‚Äôs review, and press releases from <strong>Glenmark Pharmaceuticals Limited (GLENMARK ‚Äì Scrip Code: 532296)</strong> as of <strong>November‚ÄìDecember 2025</strong>, the following <strong>structured summary</strong> outlines the <strong>headwinds, tailwinds, growth prospects, and key risks</strong> for the company:</p>
<hr />
<div id="company-overview" class="section level6">
<h6>üîç <strong>Company Overview</strong></h6>
<ul>
<li><strong>Segment</strong>: Pharmaceuticals (Generics, APIs, OTC, Specialty)</li>
<li><strong>Operations</strong>: Global (India, US, Europe, Emerging Markets)</li>
<li><strong>Segments</strong>: One reportable segment ‚Äì Pharmaceuticals</li>
<li><strong>ESG Focus</strong>: ESG committee reconstituted with strong leadership (ex-Cabinet Secretary Mr.¬†P.K. Sinha as Chair)</li>
<li><strong>R&amp;D Focus</strong>: IGI Therapeutics SA (innovation arm)</li>
<li><strong>Listed on</strong>: BSE &amp; NSE</li>
</ul>
<hr />
</div>
<div id="tailwinds-positive-catalysts" class="section level6">
<h6>‚úÖ <strong>TAILWINDS (Positive Catalysts)</strong></h6>
<div id="strong-one-off-revenue-driver-abbvie-licensing-deal" class="section level9">
<p class="heading">1. <strong>Strong One-Off Revenue Driver: AbbVie Licensing Deal</strong></p>
<ul>
<li><strong>$700M upfront payment</strong> from <strong>AbbVie</strong> for exclusive rights to develop, manufacture, and commercialize <strong>ISB 2001</strong> in major markets (North America, Europe, Japan, Greater China).</li>
<li><strong>$525 million recognized as revenue</strong> in Q2 FY26 (July‚ÄìSept 2025), providing a significant short-term top-line boost.</li>
<li>This is a <strong>high-margin, non-dilutive capital inflection point</strong> ‚Äî rare in Indian pharma ‚Äî signaling confidence in Glenmark‚Äôs R&amp;D pipeline.</li>
</ul>
<blockquote>
<p>‚úÖ <strong>Impact</strong>: Large cash inflow, improves balance sheet, enhances valuation, funds future R&amp;D.</p>
</blockquote>
<hr />
</div>
<div id="fda-regulatory-recovery-monroe-usa-facility-cleared" class="section level9">
<p class="heading">2. <strong>FDA Regulatory Recovery ‚Äì Monroe (USA) Facility Cleared</strong></p>
<ul>
<li><strong>Monroe, NC facility</strong> received <strong>EIR with Voluntary Action Indicated (VAI)</strong> status from U.S. FDA (Nov 2025) after June 2025 inspection.</li>
<li>Ends nearly <strong>2.5-year Warning Letter</strong> (since June 2023), allowing <strong>resumption of commercial manufacturing</strong>.</li>
<li>Prior Form 483 had 5 observations; clearance indicates <strong>regulatory compliance improvement</strong>.</li>
</ul>
<blockquote>
<p>‚úÖ <strong>Impact</strong>: Restores supply chain reliability, regains credibility with US generics clients, supports revenue growth.</p>
</blockquote>
<hr />
</div>
<div id="zero-fda-483-observations-at-aurangabad-facility" class="section level9">
<p class="heading">3. <strong>Zero FDA 483 Observations at Aurangabad Facility</strong></p>
<ul>
<li>Successful <strong>Pre-Approval Inspection (PAI)</strong> at <strong>Chhatrapati Sambhajinagar (Aurangabad)</strong> facility with <strong>zero observations</strong>.</li>
<li>Increases likelihood of <strong>product approvals</strong> in the pipeline and reflects strong operational compliance.</li>
</ul>
<blockquote>
<p>‚úÖ <strong>Impact</strong>: Regulatory tailwind; strengthens portfolio approval momentum in US generic market.</p>
</blockquote>
<hr />
</div>
<div id="positive-cash-flow-recovery-operating-level" class="section level9">
<p class="heading">4. <strong>Positive Cash Flow Recovery (Operating Level)</strong></p>
<ul>
<li><strong>Net cash from operating activities</strong> (Consolidated, H1 FY26): <strong>‚Çπ28,356 crore</strong></li>
<li>Marked improvement vs.¬†H1 FY25: <strong>(‚Äì‚Çπ3,635 crore)</strong></li>
<li>Adjusted for large one-offs, underlying operations show operational recovery.</li>
</ul>
<blockquote>
<p>‚úÖ <strong>Impact</strong>: Strong underlying working capital management improvement.</p>
</blockquote>
<hr />
</div>
<div id="profitability-turnaround-ex-ethics-in-standalone" class="section level9">
<p class="heading">5. <strong>Profitability Turnaround (Ex-Ethics) in Standalone</strong></p>
<ul>
<li>Despite extraordinary charges, <strong>base profitability recovering</strong>:
<ul>
<li><strong>PBT before exceptional items</strong>: ‚Çπ7,498 crore (Half-year, standalone, up 5.3% YoY)</li>
<li>Core operations stable amid pricing pressures.</li>
</ul></li>
</ul>
<blockquote>
<p>‚úÖ <strong>Impact</strong>: Foundational strength in business model persists.</p>
</blockquote>
<hr />
</div>
<div id="dividend-payout-credibility" class="section level9">
<p class="heading">6. <strong>Dividend Payout Credibility</strong></p>
<ul>
<li><strong>Interim dividend of ‚Çπ2.50/share</strong> (‚Çπ705.5 crore) approved.</li>
<li>Signals confidence in liquidity and shareholder returns.</li>
</ul>
<hr />
</div>
</div>
<div id="headwinds-challenges-drags" class="section level6">
<h6>‚ùå <strong>HEADWINDS (Challenges &amp; Drags)</strong></h6>
<div id="massive-exceptional-charges-litigation-reserves" class="section level9">
<p class="heading">1. <strong>Massive Exceptional Charges (Litigation Reserves)</strong></p>
<div id="q2-fy26-charges" class="section level12">
<p class="heading">Q2 FY26 Charges:</p>
<ul>
<li><strong>Standalone &amp; Consolidated exceptional loss</strong>: <strong>‚Çπ9,318 crore (Q2)</strong> / ‚Çπ1,792 crore (H1 vs.¬†prior H1)</li>
<li>Key components:
<ul>
<li><strong>‚Çπ9,318 crore</strong>: New <strong>U.S. antitrust settlement</strong> with <strong>United Healthcare Services Inc.¬†(last opt-out plaintiff)</strong>: ‚Çπ976 crore provision + associated costs.</li>
<li><strong>‚Çπ5,901 crore</strong>: Inventory write-offs post <strong>GST 2.0</strong> and new inventory management model.</li>
<li><strong>‚Çπ4,885 crore</strong>: Receivables &amp; current asset provisions.</li>
<li><strong>‚Çπ2,089 crore</strong>: PPE impairment.</li>
</ul></li>
</ul>
<blockquote>
<p>‚ùå Impacts net profit:<br />
- <strong>Standalone PAT Q2</strong>: <strong>(‚Çπ7,392 crore)</strong> loss vs.¬†‚Çπ3,302 crore profit Q1<br />
- <strong>EPS (Basic)</strong>: <strong>‚Çπ(26.19)</strong> down from ‚Çπ11.70</p>
</blockquote>
<blockquote>
<p>‚ö†Ô∏è <strong>Note</strong>: These are non-recurring but extremely heavy; may skew investor perception.</p>
</blockquote>
<hr />
</div>
</div>
<div id="impaired-us-litigation-cloud" class="section level9">
<p class="heading">2. <strong>Impaired US Litigation Cloud</strong></p>
<ul>
<li>Multiple antitrust suits in the U.S. (generic drug pricing allegations).</li>
<li>Total settlements across FY24‚ÄìFY26 exceed <strong>$132.25 million (~‚Çπ10,000 crore+)</strong>.</li>
<li>While company <strong>denies wrongdoing</strong> and cites ‚Äúcommercial settlement‚Äù, continuing reputational risk exists.</li>
</ul>
<blockquote>
<p>‚ùå Lingering ESG/litigation perception risk, especially in Western markets.</p>
</blockquote>
<hr />
</div>
<div id="restructuring-in-igi-therapeutics" class="section level9">
<p class="heading">3. <strong>Restructuring in IGI Therapeutics</strong></p>
<ul>
<li><strong>IGI TSA</strong> restructured &amp; manufacturing unit in <strong>Le-Chaux-de-Fonds (Switzerland)</strong> shut down.</li>
<li>Total exceptional cost: <strong>‚Çπ1,978 crore (FY25)</strong>.</li>
<li>CMC (Chemistry, Manufacturing, Controls) transitioned to CDMO ‚Äî long-term cost control, but near-term disruption.</li>
</ul>
<blockquote>
<p>‚ùå Signal of <strong>pipeline prioritization</strong>; non-core R&amp;D scaled back.</p>
</blockquote>
<hr />
</div>
<div id="decline-in-indian-emerging-market-revenue" class="section level9">
<p class="heading">4. <strong>Decline in Indian &amp; Emerging Market Revenue</strong></p>
<ul>
<li><strong>Domestic Formulations Growth Stagnant</strong>: Not highlighted as a driver; core Indian generic market likely facing <strong>pricing erosion</strong> and competition.</li>
<li>Exports: U.S. segment not explicitly growing ‚Äî likely under pressure from <strong>generic pricing declines</strong>.</li>
</ul>
<hr />
</div>
<div id="high-leverage-funding-needs" class="section level9">
<p class="heading">5. <strong>High Leverage &amp; Funding Needs</strong></p>
<ul>
<li>Total Financial Liabilities (Standalone): <strong>‚Çπ24,923 crore</strong></li>
<li>Net debt: Not directly stated, but significant lease and borrowing liabilities.</li>
<li>No equity fundraising disclosed, but large one-time cash inflow from AbbVie helps.</li>
</ul>
<blockquote>
<p>‚ùå Refinancing risk in medium term if earnings remain volatile.</p>
</blockquote>
<hr />
</div>
</div>
<div id="growth-prospects" class="section level6">
<h6>üìà <strong>GROWTH PROSPECTS</strong></h6>
<table>
<colgroup>
<col width="46%" />
<col width="53%" />
</colgroup>
<thead>
<tr class="header">
<th>Driver</th>
<th>Outlook</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>R&amp;D Monetization</strong></td>
<td><strong>High potential</strong> ‚Äì AbbVie deal opens door for future licensing. ISB 2001 likely an immuno-oncology/biologic asset. Pipeline focus may shift toward innovation.</td>
</tr>
<tr class="even">
<td><strong>U.S. Generic Recovery</strong></td>
<td><strong>Improving</strong> ‚Äì Monroe facility restart and successful PAI at Aurangabad indicate better regulatory compliance. New product approvals likely to resume.</td>
</tr>
<tr class="odd">
<td><strong>Emerging Markets &amp; APIs</strong></td>
<td>Stable revenue streams; not expanding but resilient.</td>
</tr>
<tr class="even">
<td><strong>ESG &amp; Sustainability Credibility</strong></td>
<td>SBTi approval strengthens ESG profile ‚Äî advantage in global institutional investing.</td>
</tr>
<tr class="odd">
<td><strong>Consumer Care Spin-off Completed</strong></td>
<td><strong>Transferred to GCCL</strong> (slump sale for ‚Çπ2,400 cr); <strong>non-material revenue</strong>, but improves strategic focus on core pharma.</td>
</tr>
</tbody>
</table>
<blockquote>
<p>üîÆ <strong>Potential Re-rating Drivers</strong>: - Sustained FDA compliance - Repeat deals from IGI TSA pipeline - Cost rationalization post restructuring</p>
</blockquote>
<hr />
</div>
<div id="key-risks" class="section level6">
<h6>‚ö†Ô∏è <strong>KEY RISKS</strong></h6>
<ol style="list-style-type: decimal">
<li><strong>Regulatory Risk (FDA Exposure)</strong>:
<ul>
<li>Despite progress, past <strong>Warning Letter</strong> history makes U.S. business vulnerable; another quality lapse could trigger backtracking.</li>
</ul></li>
<li><strong>Litigation Risk</strong>:
<ul>
<li>U.S. antitrust suits may not be fully resolved; <strong>new private lawsuits</strong> possible. Ongoing need for large provisions.</li>
</ul></li>
<li><strong>Pipeline Risk for IGI TSA</strong>:
<ul>
<li>After AbbVie deal and restructuring, future <strong>R&amp;D output</strong> may shrink unless new assets show promise.</li>
</ul></li>
<li><strong>Inventory &amp; Working Capital Volatility</strong>:
<ul>
<li>‚Çπ5,901 crore inventory provision signals <strong>legacy model inefficiencies</strong> ‚Äî GST 2.0 digitization may hit margins short-term.</li>
</ul></li>
<li><strong>Currency &amp; Global Macroeconomic Risk</strong>:
<ul>
<li>~40%+ revenue from international markets ‚Äî exposure to <strong>INR appreciation, supply chain inflation, trade barriers</strong>.</li>
</ul></li>
<li><strong>Generic Price Erosion in US/EU</strong>:
<ul>
<li>Industry-wide headwind; Glenmark has limited pricing power in commoditized markets.</li>
</ul></li>
</ol>
<hr />
</div>
<div id="summary-investment-thesis-neutral-to-positive" class="section level6">
<h6>üîö <strong>SUMMARY: Investment Thesis ‚Äì Neutral to Positive</strong></h6>
<table>
<colgroup>
<col width="42%" />
<col width="57%" />
</colgroup>
<thead>
<tr class="header">
<th>Parameter</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Short-Term (6‚Äì12 months)</strong></td>
<td>‚ùó Mixed ‚Äì Heavy losses from exceptional items may spook market, but <strong>Abbvie cash infusion and FDA recovery</strong> are strong positives.</td>
</tr>
<tr class="even">
<td><strong>Medium-Term (1‚Äì3 years)</strong></td>
<td>‚úÖ Positive ‚Äì Regulatory recovery should boost U.S. sales; cost optimization post-restructuring; potential for more IP monetization.</td>
</tr>
<tr class="odd">
<td><strong>Valuation</strong></td>
<td>Likely depressed due to one-time losses; <strong>actual operating EPS &gt; ‚Çπ50/share annualized</strong>. Could be undervalued if turnaround holds.</td>
</tr>
<tr class="even">
<td><strong>Best Case</strong></td>
<td>Glenmark replicates IGI model with new assets, wins U.S. approvals, deleverages. ‚Üí <strong>Stock re-rating</strong>.</td>
</tr>
<tr class="odd">
<td><strong>Worst Case</strong></td>
<td>New FDA observations, more litigation, or poor R&amp;D output ‚Üí <strong>continuing volatility</strong>.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="final-conclusion" class="section level6">
<h6>üí° <strong>Final Conclusion</strong></h6>
<p><strong>Glenmark is at an inflection point</strong>: - <strong>Massive headwinds</strong> from legacy litigation and inventory writedowns have caused short-term pain. - But <strong>strong tailwinds</strong> ‚Äî the <strong>$700M AbbVie deal</strong>, <strong>FDA clearance</strong>, and <strong>strategic spin-offs/restructuring</strong> ‚Äî position the company for recovery and potential transformation. - <strong>Primary growth avenue</strong> shifting from volume-driven generics to <strong>innovation-led licensing</strong>. - <strong>Investors should focus on cash flow, regulatory compliance, and next pipeline milestones</strong> rather than headline losses.</p>
<blockquote>
<p>‚úÖ <strong>Recommendation</strong>: <strong>Watchful optimism</strong> ‚Äî a turnaround play with potential for outperformance if execution improves. Suitable for <strong>value + event-driven investors</strong>.</p>
</blockquote>
<hr />
<p>Let me know if you‚Äôd like a <strong>DCF valuation</strong>, <strong>peer comparison</strong>, or <strong>visual dashboard summary (PPT/Excel)</strong> based on the data.</p>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
